JP2014515751A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515751A5
JP2014515751A5 JP2014505470A JP2014505470A JP2014515751A5 JP 2014515751 A5 JP2014515751 A5 JP 2014515751A5 JP 2014505470 A JP2014505470 A JP 2014505470A JP 2014505470 A JP2014505470 A JP 2014505470A JP 2014515751 A5 JP2014515751 A5 JP 2014515751A5
Authority
JP
Japan
Prior art keywords
seq
grf analog
ala
grf
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014505470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515751A (ja
JP6113144B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2012/050242 external-priority patent/WO2012142706A1/en
Publication of JP2014515751A publication Critical patent/JP2014515751A/ja
Publication of JP2014515751A5 publication Critical patent/JP2014515751A5/ja
Application granted granted Critical
Publication of JP6113144B2 publication Critical patent/JP6113144B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014505470A 2011-04-21 2012-04-17 成長ホルモン放出因子(grf)類似体およびその使用 Expired - Fee Related JP6113144B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477775P 2011-04-21 2011-04-21
US61/477,775 2011-04-21
PCT/CA2012/050242 WO2012142706A1 (en) 2011-04-21 2012-04-17 Growth hormone releasing factor (grf) analogs and uses thereof

Publications (3)

Publication Number Publication Date
JP2014515751A JP2014515751A (ja) 2014-07-03
JP2014515751A5 true JP2014515751A5 (enExample) 2015-06-11
JP6113144B2 JP6113144B2 (ja) 2017-04-12

Family

ID=47021786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014505470A Expired - Fee Related JP6113144B2 (ja) 2011-04-21 2012-04-17 成長ホルモン放出因子(grf)類似体およびその使用

Country Status (10)

Country Link
US (1) US8361964B2 (enExample)
EP (1) EP2699591A4 (enExample)
JP (1) JP6113144B2 (enExample)
KR (1) KR20140027284A (enExample)
CN (1) CN103547591A (enExample)
AR (1) AR087727A1 (enExample)
BR (1) BR112013027150A2 (enExample)
CA (1) CA2833434A1 (enExample)
MX (1) MX2013012259A (enExample)
WO (1) WO2012142706A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
MX2018012716A (es) * 2016-04-19 2019-02-11 Griffon Pharmaceuticals Inc Peptidos bioactivos pegilados y usos de los mismos.
CA3183299A1 (en) * 2020-07-05 2022-01-13 Christian Marsolais Low-dose pharmaceutical compositions of ghrh analogs and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518586A (en) 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4617149A (en) 1983-09-21 1986-10-14 Eli Lilly And Company Growth hormone release factor analogs
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4801456A (en) 1987-07-09 1989-01-31 International Minerals & Chemical Corp. Growth hormone-releasing factor analogs
EP0307860B1 (en) * 1987-09-18 1994-06-08 F. Hoffmann-La Roche Ag Cyclic GRF-analogs
IL97885A0 (en) * 1990-04-24 1992-06-21 Lilly Co Eli Growth hormone releasing factor analogs
CA2084061A1 (en) 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
US5262519A (en) * 1991-05-15 1993-11-16 The Salk Institute For Biological Studies GRF analogs XI
CA2218173A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
DK0828758T3 (da) 1995-05-26 2002-01-07 Theratechnologies Inc Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6057422A (en) 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
US7256258B2 (en) 2000-10-05 2007-08-14 Ares Trading S.A. Regioselective liquid phase pegylation
CA2435563A1 (en) 2001-02-02 2002-08-15 Conjuchem Inc. Long lasting growth hormone releasing factor derivatives
AU2002305845B2 (en) * 2001-06-08 2006-03-30 Ipsen Pharma S.A.S. Somatostatin-dopamine chimeric analogs
EP1539959A2 (en) 2002-09-18 2005-06-15 Centre Hospitalier de l'Université de Montréal (CHUM) Ghrh analogues
AU2003229222B2 (en) 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
WO2006042408A1 (en) 2004-10-20 2006-04-27 Theratechnologies Inc. Gh secretagogues and uses thereof
TW200517400A (en) 2003-08-05 2005-06-01 Univ Tulane Antagonistic analogs of GH-RH (2003)
US7893025B2 (en) 2003-10-20 2011-02-22 Theratechnolgies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US20090088380A1 (en) 2007-07-12 2009-04-02 Pierrette Gaudreau Ghrh analogs and therapeutic uses thereof
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
EP2421548A4 (en) 2009-04-20 2012-09-26 Theratechnologies Inc USE OF (HEXENOYL TRANS-3) HGRF (1-44) NH2 AND SIMVASTATIN IN COMBINED TREATMENT

Similar Documents

Publication Publication Date Title
JP2013515057A5 (enExample)
IL262805B1 (en) CD47 agonist factors for inducing programmed cell death and their use in the treatment of diseases associated with defects in programmed cell death
JP2013515055A5 (enExample)
TWI374030B (en) Use of melanocortins to treat insulin sensitivity
JP2014521684A5 (enExample)
JP2011526886A5 (enExample)
FI3482765T3 (fi) Pitkävaikutteinen kasvuhormoni ja menetelmiä sen tuottamiseksi
BR122020011001B1 (pt) Peptídeo derivados de oxintomodulina e seu uso, polinucleotídeo, composição farmacêutica e seu uso e método para prevenção ou tratamento da obesidade compreendendo os mesmos
JP2011511753A5 (enExample)
JP2005524648A5 (enExample)
JP2012500001A5 (enExample)
JP2018504901A5 (enExample)
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
JP2013518057A5 (enExample)
JP2007509984A5 (enExample)
JP2013517307A5 (enExample)
JP2010515686A5 (enExample)
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
JP2004504406A5 (enExample)
JP2014050390A5 (enExample)
JP2015533833A5 (enExample)
JP2009191078A5 (enExample)
JP2014530868A5 (enExample)
JP2016501204A5 (enExample)
JP2016518351A5 (enExample)